Idaho Society of Cancer Oncology

Welcome

The Idaho Society of Clinical Oncology (ISCO) represents Idaho physicians and related health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

The Benefits of Membership

Membership in the Society is open to all professionals whose primary endeavor is the delivery of oncology care,  including physicians, nurse practitioners, physician assistants and pharmacists. Membership is restricted to those individuals primarily delivering care in the State of Idaho and is FREE to qualified professionals

 

Join Today

 

Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card

Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness.

Click here for more.

CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain
Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease

Click here for more

 

Upcoming Events

ISCO Fall Meeting
November 1-2, 2019
The Grove Hotel | Boise

ASH Meeting on Hematologic Malignancies
September 6-7, 2019
Fairmont Chicago, Millennium Park, Chicago, IL


Janssen provides discussion paper for 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule. 

The CMS fact sheet is available here.  In the FY 2020 IPPS Proposed Rule, CMS addresses how the agency proposes to pay for CAR T-cell therapy administered on an inpatient basis.

Click here for more

 

COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories

COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.

Click here for more.

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments

Click here for more.